These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 10485819)

  • 1. Hepatic effects in beagle dogs administered atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, for 2 years.
    Walsh KM; Rothwell CE
    Toxicol Pathol; 1999; 27(4):395-401. PubMed ID: 10485819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A reductase inhibitor, in beagle dogs.
    Walsh KM; Albassam MA; Clarke DE
    Toxicol Pathol; 1996; 24(4):468-76. PubMed ID: 8864188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats.
    Henck JW; Craft WR; Black A; Colgin J; Anderson JA
    Toxicol Sci; 1998 Jan; 41(1):88-99. PubMed ID: 9520344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The eye lens evaluation of the atorvastatin-treated white rat.
    Zakrzewski P; Milewska J; Czerny K
    Ann Univ Mariae Curie Sklodowska Med; 2002; 57(2):165-71. PubMed ID: 12898835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin is not cataractogenic in beagle dogs.
    Robertson DG; Urda ER; Rothwell CE; Walsh KM
    Curr Eye Res; 1997 Dec; 16(12):1229-35. PubMed ID: 9426956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune hepatitis revealed by atorvastatin.
    Pelli N; Setti M; Ceppa P; Toncini C; Indiveri F
    Eur J Gastroenterol Hepatol; 2003 Aug; 15(8):921-4. PubMed ID: 12867804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
    Han KH; Rha SW; Kang HJ; Bae JW; Choi BJ; Choi SY; Gwon HC; Bae JH; Hong BK; Choi DH; Han KR
    J Clin Lipidol; 2012; 6(4):340-51. PubMed ID: 22836071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.
    Amano Y; Ishikawa E; Shinozawa E; Shimada M; Miura S; Adachi R; Tozawa R
    Life Sci; 2014 Jul; 108(1):7-12. PubMed ID: 24805868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits.
    Dostal LA; Schardein JL; Anderson JA
    Teratology; 1994 Dec; 50(6):387-94. PubMed ID: 7778043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
    Harris KP; Wheeler DC; Chong CC;
    Kidney Int; 2002 Apr; 61(4):1469-74. PubMed ID: 11918754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
    Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
    Noriega V; Pennanen C; Sánchez MP; Chiong M; Llancaqueo M; Lavandero S; Prieto JC
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):211-5. PubMed ID: 19067673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression.
    Moon JH; Kang SB; Park JS; Lee BW; Kang ES; Ahn CW; Lee HC; Cha BS
    Metabolism; 2011 Jul; 60(7):930-40. PubMed ID: 20951395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease.
    Cunningham SM; Rush JE; Freeman LM
    J Vet Intern Med; 2013; 27(4):985-9. PubMed ID: 23758137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High doses of atorvastatin (Sortis) modify the secretory process in the exocrine portion of the pancreas.
    Czerny K; Romanowska J; Kifer-Wysocka E; Matysiak W; Masłyk T
    Ann Univ Mariae Curie Sklodowska Med; 2004; 59(2):52-6. PubMed ID: 16146048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties.
    Uyuklu M; Meiselman HJ; Baskurt OK
    Clin Hemorheol Microcirc; 2007; 36(1):25-33. PubMed ID: 17211059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs.
    Aggarwal D; West KL; Zern TL; Shrestha S; Vergara-Jimenez M; Fernandez ML
    BMC Cardiovasc Disord; 2005 Sep; 5():30. PubMed ID: 16188040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
    Aoki T; Yamazaki H; Suzuki H; Tamaki T; Sato F; Kitahara M; Saito Y
    Arzneimittelforschung; 2001; 51(3):197-203. PubMed ID: 11304935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.